WCG
EBS icon

Weaver Consulting Group’s Emergent Biosolutions EBS Stock Holding History

Weaver Consulting Group’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-20
Closed -$2K – 347
2020
Q3 		$2K Buy
+20
New +$2.16K ﹤0.01% 812

Other funds holding EBS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Weaver Consulting Group's EBS Position: Q4 2020 in Review

Weaver Consulting Group sold out of Emergent Biosolutions (EBS) in Q4 2020, closing a stake of 20 shares — an estimated $2K sold.

Weaver Consulting Group first reported a position in EBS in Q3 2020 and held it in 1 quarter. The position peaked at $2K in Q3 2020. 353 funds tracked by Wall St. Rank hold EBS as of Q4 2020.

  • Weaver Consulting Group reported no remaining Emergent Biosolutions position as of Q4 2020 after selling out during the quarter.
  • Weaver Consulting Group sold 20 Emergent Biosolutions shares in Q4 2020, an estimated $2K.
  • Weaver Consulting Group first reported a position in Emergent Biosolutions in Q3 2020 and held it in 1 quarter.
  • Weaver Consulting Group's Emergent Biosolutions position peaked at $2K in Q3 2020.
  • 353 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q4 2020.

Based on Weaver Consulting Group's 13F filing for Q4 2020, filed 29 Jan 2021.